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NEUROKININ A and B are putative inflammatory mediators.
We assessed their ability to alter prenodal lymphatic
resistance. Intralymphatic neurokinin A (3.0 10 -6, 3.0
10-s and 3.0 10-4 mol 1-1) significantly constricted
lymphatics at the two highest doses. Preliminary experi-
ments suggested that neurokinin B might dilate lympha-
tics. To test this, lymphatic pressure was increased by
norepinephrine (3.1 10
-6 mol 1-1). Neurokinin B
(2.7 10-4 mol 1-1) was then infused intralymphatically
during norepinephrine infusion. Norepinephrine in-
creased perfusion pressure from 5.6 0.6mmHg to
12.1 _+ 1.4 mmHg. Subsequent infusion of neurokinin B
significantly decreased lymphatic perfusion pressure from
11.9 + 1.3 mmHg to 9.9 + 1.1 mmHg. These data indicate
that neurokinin A and B can alter lymphatic resistance and
are consistent with the hypothesis that lymph vessel func-
tion may be subject to modulation by neurokinins.
Key words: Canine forelimb, Lymphatic constriction, Lym-
phatic resistance, Lymphatic smooth muscle, Lymph vessel
function, Neurokinins, Tachykinins.
Neuropeptide modulation of
lymphatic smooth muscle tone
in the canine forelimb
David E. Dobbins
Department of Physiology, Uniformed Services
University of the Health Sciences,
4301 Jones Bridge Road, Bethesda,
M D 20814-4799, USA
cA Corresponding Author
Introduction
Neurokinin A (also known as substance K) and
neurokinin B (also known as neuromedin K) are
both ten amino acid peptides of the tachykinin
family which were originally isolated from
mammalian spinal cord by Kimura et al. in 1983.
The distribution of the neurokinins in both the
central and peripheral nervous systems has been
reported to be similar to that of substance P, the
prototype of the tachykinin family.
2 The concentra-
tion of these peptides in perivascular nerve
terminals impinging upon the resistance vessels of
the peripheral circulation has led to the suggestion
that they play a role in the modulation of the
circulation. 3’4 Additionally, evidence is accumula-
ting which suggests that alterations in tachykinin
levels may play a role in a multitude of
pathophysiological conditions.3’sq
We have previously shown that the intra-arterial
infusion of nanogram quantities of neurokinin A
and B results in potent vasodilation in the skin and
skeletal muscle circulations of the canine forelimb.
Although the vascular actions of these neuropep-
tides have begun to be delineated, no work has yet
been published concerning the possible impact of
these agents on lymphatic vessel function via
alterations in lymphatic smooth muscle tone.
Previous reports have revealed that the central
lacteal lymphatics of canine ileal and duodenal
villi12’13 and the lymphatic capillaries in rat liver4
are innervated with nerves which contain tachyki-
nins. These findings indicate that these vessels
(C) 1992 Rapid Communications of Oxford Ltd
might be subject to control, at least in part, by
tachykinins.
A wide array of endogenous vasoactive agents
including catecholamines,
5 autacoids,
16 inflamma-
tory mediators,
16 prostanoids
17 and endothelin
8 are
capable of increasing lymphatic resistance when
administered either intralymphatically or intra-
arterially. In the current study we assessed the
ability of intralymphatically infused neurokinin A
and B to alter lymphatic smooth muscle tone in
perfused prenodal lymphatic vessels.
Materials and Methods
Adult mongrel dogs of either sex were anaesthe-
tized with sodium pentobarbital (35 mg kg
-1 i.v.
and supplemented as needed), intubated and venti-
lated with room air. Small incisions were made
in the skin of the right forelimb and the brachial
artery. A small side branch of the brachial artery
and a skin small vein and artery in the paw were
isolated. The forelimb was perfused at constant
arterial inflow via the brachial artery with blood
obtained from a cannulated femoral artery.
Forelimb perfusion pressure was measured from the
side branch of the brachial artery, and skin small
vein and artery pressures were measured on the
dorsal and ventral surfaces of the paw respectively.
Systemic arterial pressure was measured by
inserting a catheter into the brachial artery and
advancing it into the aorta. A catheter was inserted
into the left external jugular vein and advanced to
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the level of the right atrium for measurement of response to neurokinin B had been obtained, the
central venous pressure, lymphatic was again perfused with control perfusate
A lymph vessel on the dorsal surface of the paw while the intra-arterial infusion of norepinephrine
was cannulated in the direction of normal lymph continued. This manoeuvre was performed to
flow. The lymph vessel was perfused at constant ensure that the decrease in lymphatic perfusion
flow at a volume flow rate of 0.034 ml min
-1 with pressure seen during neurokinin B infusion was
a perfusate which was the supernatant of a 1"1 indeed caused by neurokinin B and not merely a
mixture of autologous arterial blood and hepar- dissipation of the effects of norepinephrine. When
inized Krebs solution. Lymphatic perfusion pres- lymphatic perfusion pressure had again reached a
sure was measured from the perfusion system at a steady state, the intra-arterial infusion of nor-
point upstream to the point of cannulation of the epinephrine was discontinued and lymphatic
prenodal lymph vessel. A three-way stopcock, perfusion pressure was allowed to return to control
which had been modified such that all three ports values.
were confluent, allowed for measurement of The effects of a single dose of substance P, the
lymphatic perfusion pressure and for the lymphatic prototype of the tachykinin peptide family, was also
to be perfused with either control perfusate or tested for its ability to alter lymphatic resistance.
perfusate containing tachykinins. Following acquisition of control values, substance
The protocol was as follows" in all experiments, P at a concentration of 2.4 10-4 mol 1-1 was
the lymph vessel was perfused with control infused intralymphaticallyforaminimumof15 min
perfusate for a minimum of 15 min to ensure that or until the peak response was obtained. Following
all measured pressures had reached steady state the conclusion of the substance P infusion, the
values. In the neurokinin A experiments, the lymph lymphatic vessel was again perfused with control
vessel was then perfused with a solution containing perfusate until all measured pressures returned to
neurokinin A at 3.0 10
-6 3.0 x 10
-5 or control values.
3.0 10-4 mol 1-1 for a minimum of 15 min or Norepinephrine, neurokinin A, neurokinin B and
until the peak response in lymphatic perfusion substance P were made up fresh daily in normal
pressure had been obtained. The lymphatic was saline in a stock solution of 1.5 mg m1-1. Final
then perfused with control perfusate until the dilutions of norepinephrine were made in normal
lymphatic perfusion pressure returned to control saline and it was infused into the arterial blood
values. Early experiments revealed that neurokinin supply to the forelimb with a needle tipped catheter.
A shares, with histamine and angiotensin II, the Final dilutions of the tachykinins were made by
characteristic of altering lymphatic perfusion adding the appropriate amount of the lymphatic
pressure upon its initial infusion but thereafter perfusate. All data were analysed using Student’s t
renders the lymph vessel insensitive to infusion of test as modified for paired replicates. Pressures
the same agent even at concentrations several orders obtained immediately prior to an experimental
of magnitude higher. Therefore, the three point manoeuvre were compared with those achieved
dose-response relationship to neurokinin A had to during the peak of the response seen during the
be generated in three separate (n 7) series of manoeuvre.
animals to ascertain the actual potency of this agent
in altering prenodal lymphatic resistance. Results Preliminary experiments with the intralymphatic
infusion ofneurokinin B suggested that this peptide The infusion of neurokinin A at the lowest
would likely dilate lymphatic vessels. Since the infusion rate did not significantly alter lymphatic
control pressure in these vessels as perfused in this perfusion pressure (Figure 1) from its control value
study is relatively low (4-5 mmHg on average) it of 5.7 + 0.6 mmHg. However, infusion of the
appeared best to first increase the lymphatic middle dose ofneurokinin A significantly increased
perfusion pressure with the intra-arterial infusion of lymphatic pressure from a control value of
a known lymphatic constrictor agent and then
infuse neurokinin B intralymphatically in the face
of the steady but elevated lymphatic perfusion
pressure. To this end, in the neurokinin B
experiments, norepinephrine was infused intra-
arterially at a concentration of 3.1 x 10
-6 mol 1-1.
When the lymphatic perfusion pressure had reached
a steady elevated value, neurokinin B was
6.7 -+- 0.8 mmHg to a peak pressure of
8.0 0.8 mmHg. The highest dose of neurokinin
A resulted in a doubling of lymphatic resistance,
increasing lymphatic perfusion pressure from a
control value of 6.3 _+ 0.9 mmHg to a peak value
of 12.3 1.7 mmHg. It should be remembered that
these data were generated in three separate groups
of animals and thus variations in the control
infused intralymphatically at a concentration of lymphatic perfusion pressure do not reflect an
2.7 10 -4 mol 1-1 during the continued intra- instability within the preparations with time but
arterial infusion of norepinephrine. After the peak rather indicate minor ditterences in control
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FIG. 1. Effects of the intralymphatic infusion of neurokinin A on lymphatic
perfusion pressure, n=7 in three separate groups of animals.
p < 0.05, Student’s paired
lymphatic resistances between different groups of
animals. The intralymphatic infusion of neurokinin
A did not significantly alter either mean systemic
arterial, central venous or forelimb perfusion, small
artery or vein pressures (Table 1).
In the neurokinin B experiments, the intra-
arterial infusion of norepinephrine resulted in a
significant increase in lymphatic perfusion pressure
from a control value of 5.6 -t- 0.6 mmHg to a peak
pressure of 12.1 -+- 1.4 mmHg (Figure 2). Systemic
pressure, forelimb perfusion, skin small artery and
vein pressures were all significantly increased (Table
2). The intralymphatic infusion of neurokinin B
during the continued infusion of norepinephrine
resulted in a significant decrease in lymphatic
perfusion pressure from its pre-neurokinin level of
11.9 q-1.3 mmHg to a nadir of 9.9 _+ 1.1 mmHg
(Figure 2). Intralymphatic infusion of neurokinin B
did not aflect significantly any of the measured
vascular pressures (Table 2). When the lymphatic
was again perfused with control perfusate during
the continued infusion of norepinephrine, lympha-
tic perfusion pressure returned to its pre-neurokinin
levels. This indicated that the decrease observed
during infusion of neurokinin B was not simply a
waning of the effects of norepinephrine on the
lymphatic. When the intra-arterial infusion of
norepinephrine was terminated, lymphatic perf-
usion pressure returned rapidly to its pre-
norepinephrine level.
The intralymphatic infusion of substance P at
2.4 x 10-4 mol 1-1 (n 6) did not significantly
change lymphatic perfusion pressure from its
control value of 4-t-0.4mmHg and did not
significantly alter any of the measured vascular
pressures.
Discussion
The localization of neurokinins in perivascular
nerve terminals innervating the peripheral circula-
tion has led to the suggestion that these endogenous
peptides may modulate the peripheral circulation
under either normal or pathophysiological condi-
tions. However, a role for these potent vasoactive
agents in health or disease has not yet been
established. The increase in tachykinin levels in the
synovial fluid of patients with osteoarthritis and
rheumatoid arthritis,
19 and the known role of
substance P, the prototype of the tachykinin family,
in neurogenic inflammation2-22 has led to the
suggestion that these agents might alter transvascu-
lar fluid and macromolecular flux. Gamse and Saria7
have reported that neurokinin A and B produce
plasma protein extravasation in rat abdominal skin
and Fuller et al.
23 noted that the neurokinins
produce a weal and flare when injected into human
skin. However, preliminary experiments conducted
in our laboratory indicated that the neurokinins do
not increase skin lymph flow or its protein
concentration in the canine forelimb as would be
expected with agents which increase microvascular
permeability. These data are consistent with
previously published experiments
24 which indicated
Table 1. Effect of intralymphatic neurokinin A infusion on vascular pressures, n 7 in each
of three separate groups
3.0x 10-6 3.0x 10-5 3.0x10-4
C P C P C P
Sys 128 ___
4.6 128 _+ 4.1 128 +_ 2.2 127 +_ 2.3 130 +_ 2.5 129 +_ 2.5
Perf 109 _+ 5.6 112 _+ 6.2 110 _+ 3.3 113 _+ 3.9 117 _+ 6.0 116 _+ 4.9
Ssa 80 +_ 3.2 81 +_ 3.2 88 +_ 3.9 91 +_ 5.1 94 +_ 3.3 94 +_ 2.8
Ssv 9 ___
0.6 9 _+ 0.6 10 _+ 0.3 10 _+ 0.3 9 __+ 0.6 9 _+ 0.6
Cv 2 _+ 0.1 2 _+ 0.1 3 ___
0.5 3 _+ 0.5 4 + 0.5 4 _+ 0.4
Sys mean systemic, Perf forelimb perfusion, Ssa skin small artery, Ssv skin small vein,
Cv=central venous. Pressures are means+_SEM expressed in mmHg. *=p<_0.05
Student’s paired t. C control, P peak pressure. Concentration of neurokinin A is in mol I-1
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FIG. 2. Effects of the intra-arterial infusion of norepinephrine at
3.1 x 10-6 mol 1-1 and intralymphatic infusion of neurokinin B at
2.7 x 10-4 moll -1 during continued norepinephrine infusion on
lymphatic perfusion pressure, n 6, p _< 0.05, Student’s paired
that substance P likewise fails to increase lymph
flow and its protein concentration in the canine
forelimb. However, vasoactive agents can also alter
fluid transport by altering the lymphatic vessel’s
ability to transport fluid. In light of the fact that
previous experiments have revealed that some
lymphatic vessels are innervated with tachykinin
containing nerves,
12<4 this study was undertaken to
ascertain if neurokinins could influence fluid
dynamics through alterations in lymphatic smooth
muscle tone.
The experiments in this study clearly indicate that
both neurokinin A and neurokinin B are capable of
altering lymphatic resistance. The intralymphatic
infusion of neurokinin A results in significant
increases in lymphatic resistance with a threshold
dose between 3.0 x 10-6 and 3.0 x 10
-5 mol 1-1.
At the highest infusion rare utilized, neurokinin
infusion results in a doubling of lymphatic
resistance. We have previously reported that a wide
array of vasoactive agents are capable of constrict-
Table 2. Effects of intra-arterial norepinephrine and intra-
lymphatic neurokinin B on vascular pressure, n 6
Norepinephrine Neurokinin B
C P C P
Sys 124 4- 6.8 131 4-_ 6.7 127 -t- 6.4 127 4- 6.4
Perf 117 4- 8.0 225* 4- 10.0 206 -t- 7.3 205 4- 7.5
Ssa 78 4- 9.8 179* 12.9 157 _+ 13.2 157 _+ 13.2
Ssv 11 4- 0.7 19* _+ 3.3 16 4- 1.5 16 -t- 1.5
Cv 4 4- 0.01 4 4- 0.01 4 -I- 0.01 4 _+ 0.01
Sys mean systemic, Perf forelimb perfusion, Ssa skin
small artery, Ssv--skin small vein, Cv central venous. All
pressures are means 4- SEM expressed in mmHg. p _< 0.05
Student’s paired t. C control, P peak pressure.
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ing prenodal lymphatic vessels in the canine
forelimb.
15-18 The threshold concentrations at
which significant lymphatic constriction is manifest
varies widely among vasoactive agents, from the
extremely potent lymphatic constrictor endothelin
(threshold concentration between 10
-l and 10
-9
mol 1-1) to markedly less potent agents such as
prostaglandin E1 (threshold concentration between
10-4 and 10
-3 mol 1-1). The current study indicates
that the threshold concentration of neurokinin A
required to obtain significant lymphatic constriction
(10
-6 to 10 -s mol 1-1) lies in the middle range of
tested agents and is comparable to that seen with
bradykinin, dopamine and acetylcholine. However,
precise conclusions as to the potency of neurokinin
A as a lymphatic constrictor are difficult to make.
Since neurokinins are located in nerve endings, the
lymphatic perfusate concentrations of these com-
pounds which are reported in this study to be
effective in altering lymphatic smooth muscle tone
may not accurately reflect their true effective
concentrations at their effector site on the
lymphatic smooth muscle. The effective concentra-
tions at the point of release on the lymphatic
smooth muscle cell may well be substantially lower
than effective circulating concentrations.
The current study also indicates that intra-
lymphatic infusion of neurokinin B is capable of
producing a significant decrease in lymphatic
resistance. This is best seen, in light of the control
lymphatic perfusion pressures involved, in pre-
constricted lymph vessels. In this respect, neuro-
kinin B is similar in action to the fl2-receptor agonist
terbutaline
25 and to adenosine which also signifi-
cantly relax pre-constricted lymphatics. The con-
centration of neurokinin B which is needed to
produce significant relaxation of pre-constricted
lymphatic vessels is similar to that required for both
adenosine and terbutaline.
Preliminary studies with substance P in this
experimental model had suggested that it did not
significantly alter lymphatic perfusion pressure. In
this study, to clarify that point, we assessed the
actions of a single dose of substance P given
intralymphatically. Indeed, as suspected, substance
P did not significantly alter lymphatic perfusion
pressure. Therefore, it appears that while neuro-
kinin A and neurokinin B administered intra-
lymphatically in adequate doses can alter
lymphatic resistance, substance P in comparable
doses does not. Since substance P, neurokinin A
and neurokinin B are known to be the preferred
ligands for the NK-1, NK-2 and NK-3 tachykinin
receptors respectively, it could be speculated that
the prenodal lymph vessels in the canine forelimb
contain NK-2 and NK-3 receptors but not NK-1
receptors. However, this cannot be determined by
the results of the current study and will requireNeurokinin modulation of lymph vessels
additional experimentation utilizing specific neuro-
kinin-receptor agonists.
As stated previously, a precise physiological role
for the neurokinins has not yet been established
firmly but several lines of evidence have implicated
these peptides in control of the peripheral
circulation. Sann et al. 4 noted that the plantar
capillary blood flow in rats was significantly less in
a leg whose sciatic nerve had been treated with
capsaicin (an agent known to deplete nerves of
tachykinins) than in the contralateral untreated leg.
They thus concluded that capsaicin sensitive
peptidergic afferents may contribute to regional
blood flow control in the skin. Neurokinins may
also play a role in the nonadrenergic noncholinergic
excitatory control of the airways. Thompson et al.
26
reported that tachykinin depletion significantly
modifies the nonadrenergic, noncholinergic excita-
tory responses in guinea-pig trachea.
A role for the tachykinins in pathophysiological
states has also been proposed. Barnes has suggested
that these neuropeptides may be involved in
neurogenic inflammatory reactions in asthma.
Uchida et al.27 noting that neurokinin A is released
by chemical irritants such as cigarette smoke
suggested that neurokinin A and other tachykinins
may mediate the subendothelial oedema caused by
cigarette smoke. Lundin et al.
28 reported that the
severity of carcinoid heart disease was correlated to
the degree to which plasma levels of serotonin and
tachykinins were elevated. It has been suggested
that tachykinin-mediated stimulation of fibroblasts
may increase fibrosis of the valves in carcinoid heart
disease. Krause et al. reported that the circulating
levels of substance P more than triple in haemorr-
hagic shock. Since neurokinin A and neurokinin B
appear to be co-localized with substance P and are
released by common stimuli such as capsaicin, it is
likely that neurokinin levels would likewise be
elevated in shock.
The results of previously published work clearly
indicate that neurokinin A and neurokinin B have
potent cardiovascular effects. Their potent vasodila-
tory actions make them candidate modulators of the
peripheral circulation in either health or numerous
disease states. Additionally, the current study
suggests that they may also play a role in control
of lymphatic vessel function via alterations in
lymphatic smooth muscle tone. By way of their
actions to influence the ability of the lymph vessels
to transport fluid, these agents could impact
transvascular fluid flux and oedema formation. In
addition, their potent vasodilatory effects could act
to supplement the increase in transvascular fluid and
macromolecular flux produced by inflammatory
mediators through an increase in blood flow and
perfused capillary surface area. However, additional
studies will be required before a firm role for the
neurokinins can be established. Measurement of
circulating levels of neurokinins under various
pathophysiological conditions is needed to de-
termine under what conditions these agents are
released and to determine what circulating
concentrations are obtained. Also, a continued
refinement in the development of specific neuro-
kinin receptor agonists, antagonists and specific
releasing agents is required to firmly establish the
role of these neuropeptides in modulation of the
peripheral circulation under a myriad of conditions.
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